Re part B. Unfortunately I don't think that the FDA could grant a EUA without legislation change for aGVHD.
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
MSB have done their homework.
I believe that they may be planning a two pronged approach to the FDA'S type A meeting. Remember that the interim analysis of the ARDS trial is due early next month. That may well satisfy the FDA guide lines for unconditional approval for both ARDS and aGVHD . We would then have two successful P3 trials using remestemcell, one is the randomised controlled study that the FDA demand
The other competitors product got approved on this basis despite safty concerns.
All in my opinion, the stars are aligning in perfect formation. Good luck.
- Forums
- ASX - By Stock
- MSB
- MSB to dispute FDA finding in Type A meeting
MSB to dispute FDA finding in Type A meeting, page-431
-
- There are more pages in this discussion • 587 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
1 | 20000 | 1.175 |
1 | 5664 | 1.170 |
1 | 17568 | 1.160 |
3 | 56695 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 59712 | 2 |
1.195 | 36255 | 5 |
1.200 | 404381 | 31 |
1.205 | 3000 | 1 |
1.210 | 162475 | 7 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |